Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum Lipids: A double-blinded, randomized, placebo controlled study (Retracted Article)
Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum Lipids: A double-blinded, randomized, placebo controlled study (Retracted Article)
复制标题
DOI：
10.1016/j.jacl.2014.08.001
复制
发表时间：
2014-12-01
影响因子：
4.4
通讯作者：
Martinez, Luis
中科院分区：
文献类型：
--
作者：
Bernstein, Adam M.;Roizen, Michael F.;Martinez, Luis
背景技术背景：纯化棕榈油酸（16 - 1; omega-7）已经在开放标签、流行病学和动物研究中显示出降脂和抗炎的益处。目的：我们的目的是在人类中进行第一次纯化棕榈油酸补充剂的随机对照试验。有血脂异常和轻度全身炎症证据的成人（高敏C反应蛋白[hs-CRP]在2和5 mg/L之间）被随机分配接受220.5 mg顺式棕榈油酸（n = 30）或相同的胶囊与安慰剂（1000 mg中链甘油三酯，n = 30），每天一次，持续30天。参与者被要求保持目前的饮食。在基线和研究完成时抽取血脂和hs-CRP。结果：在30天时，（95%置信区间[CI]）CRP降低（-1.9 [-2.3至-1.4] mg/L），甘油三酯（-30.2 [-40.2至-25.3] mg/dL）和低密度脂蛋白（LDL）（-8.9 [-12.0至-5.8] mg/dL），高密度脂蛋白（HDL）显著增加（2.4 [1.5，3.3] mg/dL）。这些变化相当于44%，15%，和8%的CRP，甘油三酯和LDL分别减少，和5%的HDL增加与controls.CONCLUSIONS：纯化棕榈油酸可能是有用的高脂血症的治疗与有益的附加效果，降低LDL和hs-CRP和提高HDL。需要进一步研究以阐明机制并确定适当的人体剂量。(C)2014年国家脂质协会。All rights reserved.
BACKGROUND: Purified palmitoleic acid (16-1; omega-7) has shown lipid-lowering and anti-inflammatory benefits in open label, epidemiologic, and animal studies.OBJECTIVE: Our objective was to perform the first randomized controlled trial of purified palmitoleic acid supplementation in humans.METHODS: Adults with dyslipidemia and evidence of mild systemic inflammation (high-sensitivity C-reactive protein [hs-CRP] between 2 and 5 mg/L) were randomly allocated to receive either 220.5 mg of cis-palmitoleic acid (n = 30) or an identical capsule with placebo (1000 mg of medium chain triglycerides, n = 30) once per day for 30 days. Participants were asked to maintain their current diet. Serum lipids and hs-CRP were drawn at baseline and study completion.RESULTS: At 30 days, there were significant mean (95% confidence interval [CI]) reductions in CRP (-1.9 [-2.3 to -1.4] mg/L), triglyceride (-30.2 [-40.2 to -25.3] mg/dL), and low-density lipoprotein (LDL) (-8.9 [-12.0 to -5.8] mg/dL), and a significant increase in high-density lipoprotein (HDL) (2.4 [1.5, 3.3] mg/dL) in the intervention group compared with control. These changes equated to 44%, 15%, and 8% reductions in CRP, triglyceride, and LDL respectively, and a 5% increase in HDL compared with control.CONCLUSIONS: Purified palmitoleic acid may be useful in the treatment of hypertriglyceridemia with the beneficial added effects of decreasing LDL and hs-CRP and raising HDL. Further study is needed to elucidate mechanisms and establish appropriate human doses. (C) 2014 National Lipid Association. All rights reserved.